

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : **Oliver Yoa-Pu HU et al.**

Attorney Docket: 39297-174170

Serial No: **TO BE ASSIGNED**

Art Unit: **TO BE ASSIGNED**

Filed: **February 22, 2002**

Examiner: **TO BE ASSIGNED**

For: **Dermal Cytochrome P450 1A Inhibitors and Enhancers**

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.56, 1.97, and 1.98**

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

In compliance with the dictates of 37 C.F.R. § 1.56, 1.97, and 1.98, Applicant hereby submits an Information Disclosure Statement. The attached listing is submitted with the desire that the Examiner considers the information and that the references considered be printed on any resulting patent. It is respectfully requested that the Examiner indicate such consideration by enclosing an appropriately initialed copy of the enclosed form PTO-1449 with the next communication from the Patent Office.

The Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 22-0261.

Respectfully submitted,



Fei-Fei Chao, Ph.D.
Attorney of Record
Reg. No. 43,538

Date: February 22, 2002

Venable, Baetjer, Howard & Civiletti, L.L.P.
1201 New York Avenue, N.W., Suite 1000
Washington, D.C. 20005
(202) 216-8011

10/07/94 16
JC828 U.S. PTO
02/22/02

#3
SUGGS
4/10/02